We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Metapneumovirus Detected in Patient Specimens Within Fifteen Minutes

By LabMedica International staff writers
Posted on 31 Mar 2009
An identification kit detects and identifies human metapneumovirus (hMPV) from nasal and nasopharyngeal swabs, aspirates, and washes using hMPV monoclonal antibodies.

The D3 DFA Metapneumovirus identification kit can be used in direct testing of patient specimens with results in as fast as 15 minutes, or in cell culture with the R-Mix and R-Mix Too Mixed FreshCells cell culture systems for overnight results.

Diagnostic Hybrids (Athens, OH, USA) received U.S. More...
Food and Drug Administration (FDA; Rockville, MD, USA) clearance for the D3 DFA identification kit. The complete respiratory testing system, including additional D3 DFA respiratory testing kits, is available in the United States, Canada, and select international markets.

Human metapneumovirus (hMPV) is a respiratory viral pathogen that causes a spectrum of illnesses ranging from asymptomatic infection to severe bronchiolitis. The pathophysiology of hMPV infection is thought to be closely related to the other common human pneumovirus, respiratory syncitial virus (RSV). Like RSV, hMPV has a tropism for the respiratory epithelium. The patient may be asymptomatic, or symptoms may range from mild upper respiratory tract symptoms to severe bronchiolitis and pneumonia.

Most laboratories do not routinely test for Metapneumovirus. According to Steve Ewers, senior product manager at Diagnostic Hybrids, "the primary reason for this has been the absence of an FDA-cleared, reliable rapid assay. The D3 DFA Metapneumovirus identification kit provides the laboratory with an easy-to-perform, proven methodology utilizing the same protocol as the gold standard D3 Ultra DFA Respiratory Virus screening & identification kit. The consistency in methods will allow for easy integration into the lab workflow."

Diagnostic Hybrids invents, develops, manufactures, and sells innovative diagnostic and analytical products for a wide range of viral respiratory diseases, herpes virus infections, and other specific viral and thyroid diseases. The company also develops and commercializes innovative and genetically engineered cell-based detection products for the pharmaceutical and biotechnology industries, with an initial focus on pharmacology assays and products that measure drug clearance and anti-viral interventions with drugs and vaccines.

Related Links:

Diagnostic Hybrids
U.S. FDA




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.